• Muhammet Mucip Efe, Aydın Akyüz, Cihan Aydın, Aykut Demirkıran, and Şeref Alpsoy.
• Namık Kemal University, Faculty of Medicine, Department of Cardiology - Tekirdağ, Turkey.
• Rev Assoc Med Bras (1992). 2024 Jan 1; 70 (8): e20240515e20240515.

ObjectiveCoronary artery disease (CAD) is frequent, but coronary slow flow (CSF) is a less common cardiovascular disease with a significant risk of mortality and morbidity. Endocan is a proinflammatory glycopeptide that has been investigated in cardiovascular diseases as well as some inflammatory diseases in recent years. We planned to compare the levels of endocan in both CAD and CSF in a similar population and examine the relationship of endocan with additional clinical variables.Materials And MethodsIn the trial, we included 169 consecutive subjects having a coronary angiography indication. According to the results of coronary angiography, 58 people were included in the CAD group, 52 were in the CSF group, and 59 people were in the control group. The control group includes those who did not have any lesions in their epicardial coronary arteries. Thrombolysis in myocardial infarction (TIMI)-frame counts (TFC) were calculated for all patients.ResultsNotably, 2.6% of the population in our study had CSF. Both the CAD (555±223 pg/mL) and CSF (559±234 pg/mL) groups had higher endocan levels than the control group (331±252 pg/mL) (p<0.001). There were similar endocan levels between the CAD and CSF groups. Endocan levels were shown to be favorably associated with mean TFC (r=0.267; p0.001). Serum endocan levels (particularly those above 450 pg/mL) and the presence of hyperlipidemia were the most important predictors of both CAD and CSF.ConclusionEndocan levels are higher in CAD and CSF patients than in those with normal coronary arteries.

26 keywords...

hide…